Clinical Trial Update: Phase II Study of Neoadjuvant Tislelizumab Plus Radiotherapy and GP Chemotherapy for Borderline/Unresectable Hilar Cholangiocarcinoma [Phase 2]

View source ↗

Summary

A Phase II neoadjuvant trial evaluating tislelizumab with radiotherapy and gemcitabine/cisplatin chemotherapy for borderline/unresectable hilar cholangiocarcino…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• CISPLATIN (cisplatin)
• Gemcitabine (Gemcitabine)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Jinbo Yue | Conditions: Cholangiocarcinoma, Hilar Cholangiocarcinoma | Phase 2 | Status: NOT_YET_RECRUITING